RCT Not RWE: Two Year Report Card For The Cancer Drugs Fund Reforms

October 4, 2018 Danielle Twigg

Educational poster presented at ISPOR Meeting, Barcelona, November 2018

Previous Article
European Conditional Marketing Authorization – Does Early Marketing Authorization Translate Into Early Reimbursement And Patient Access?
European Conditional Marketing Authorization – Does Early Marketing Authorization Translate Into Early Reimbursement And Patient Access?

Next Article
NICE And The Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions In Oncology?
NICE And The Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions In Oncology?